No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
MFA MFA Financial
- 10.540
- -0.060-0.57%
Close Jul 3 13:00 ET
- 10.565
- +0.025+0.24%
Post 14:22 ET
1.08BMarket Cap-351333P/E (TTM)
10.650High10.520Low366.53KVolume10.600Open10.600Pre Close3.87MTurnover0.36%Turnover Ratio22.91P/E (Static)102.08MShares11.04352wk High0.57P/B1.06BFloat Cap7.65452wk Low1.40Dividend TTM100.63MShs Float20.214Historical High13.28%Div YieldTTM1.23%Amplitude0.800Historical Low10.570Avg Price1Lot Size
Post-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
MFA Financial To Go Ex-Dividend On June 28th, 2024 With 0.35 USD Dividend Per Share
June 26th (Eastern Time) - $MFA Financial(MFA.US)$ is trading ex-dividend on June 28th, 2024.Shareholders of record on June 28th, 2024 will receive 0.35 USD dividend per share on July 31st, 2024. The
Press Release: MFA Financial, Inc. Announces Dividend of $0.35 per Share
MFA Financial, Inc. Announces Dividend of $0.35 per Share NEW YORK--(BUSINESS WIRE)--June 11, 2024-- MFA Financial, Inc. (NYSE: MFA) announced today that its Board of Directors has declared a regula
Express News | JMP Securities Reiterates Market Outperform on MFA Finl, Maintains $12.5 Price Target
MFA Finl Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/31/2024 16.66% JMP Securities $12.5 → $12.5 Reiterates Market Outperform → Market Outperform 04/19/2024
JMP Securities Reaffirms Their Buy Rating on MFA Financial (MFA)
Express News | NYSE Order Imbalance 53646.0 Shares on Sell Side
Comments
2
$MFA Financial(MFA.US$
Pittsburghs Homewood Area!!!!
Pittsburghs Homewood Area!!!!
1
Gapping up
In reaction to earnings/guidance:
• $Thor Industries(THO.US$ +2.5%
Other news:
• $Acumen Pharmaceuticals(ABOS.US$+76.8% (in response with BIIB)
• $Biogen(BIIB.US$ +45.6% (reports Lecanemab confirmatory Phase 3 Clarity AD study met primary endpoint)
• $Nano X Imaging(NNOX.US$+22.8% (submitted a 510(k) premarket notification to the FDA on Sept 26 for its multisource 3D digital tomosynthesis system)
• $Ocugen(OCGN.US$ +9.3% (en...
In reaction to earnings/guidance:
• $Thor Industries(THO.US$ +2.5%
Other news:
• $Acumen Pharmaceuticals(ABOS.US$+76.8% (in response with BIIB)
• $Biogen(BIIB.US$ +45.6% (reports Lecanemab confirmatory Phase 3 Clarity AD study met primary endpoint)
• $Nano X Imaging(NNOX.US$+22.8% (submitted a 510(k) premarket notification to the FDA on Sept 26 for its multisource 3D digital tomosynthesis system)
• $Ocugen(OCGN.US$ +9.3% (en...
15
1
$MFA Financial(MFA.US$
$MFA Financial(MFA.US$
Transaction
Order
$MFA Financial(MFA.US$
Transaction Stats
$MFA Financial(MFA.US$
Transaction
Order
$MFA Financial(MFA.US$
Transaction Stats
loading...
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg